Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

Jennifer Howlett 1,2, Eric Benzenine 2,3, Jonathan Cottenet 2,3, Pascal Foucher 4, Philippe Fagnoni 1,5 and Catherine Quantin 2,3,6*

Abstract

Background: Venous thromboembolism (VTE) is highly prevalent in cancer patients and can cause severe morbidity. VTE treatment is essential, but anticoagulation increases the risk of major bleeding. The purpose was to evaluate the impact of VTE and major bleeding on survival and to identify significant risk factors for these events in lung cancer patients.

Methods: Data were extracted from a permanent sample of the French national health information system (including hospital and out-of-hospital care) from 2009 to 2016. All episodes of VTE and major bleeding events within one year after cancer diagnosis were identified. A Cox model was used to analyse the effect of VTE and major bleeding on the patients’ one-year survival. VTE and major bleeding risk factors were analysed with a Fine and Gray survival model.

Results: Among the 2553 included patients with lung cancer, 208 (8%) had a VTE episode in the year following diagnosis and 341 (13%) had major bleeding. Almost half of the patients died during follow-up. Fifty-six (60%) of the patients presenting with pulmonary embolism (PE) died, 48 (42%) of the patients presenting with deep vein thrombosis (DVT) alone died and 186 (55%) of those presenting with a major bleeding event died. The risk of death was significantly increased following PE and major bleeding events. VTE concomitant with cancer diagnosis was associated with an increased risk of VTE recurrence beyond 6 months after the first VTE event (sHR = 4.07 95% CI: 1.57–10.52). Most major bleeding events did not appear to be related to treatment.

Conclusion: VTE is frequent after a diagnosis of lung cancer, but so are major bleeding events. Both PE and major bleeding are associated with an increased risk of death and could be indicators of lung cancer mortality.

Keywords: Lung cancer, Venous thromboembolism, Anticoagulant therapy, Major bleeding, Medico-administrative data

* Correspondence: catherine.quantin@chu-dijon.fr
1Biostatistics and Bioinformatics (DIM), University Hospital, Bourgogne Franche-Comté University, Dijon, France
2INSERM, CIC 1432, Clinical Investigation Center, clinical epidemiology/clinical trials unit, Dijon University Hospital, Dijon, France
3Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Venous thromboembolism (VTE) is a condition which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Its annual prevalence in France has been estimated at around 180 cases (120 DVT and 60 PE) per 100,000 inhabitants [1, 2]. VTE is often asymptomatic, but the risk of recurrence and complications is high [3]. Even when it is not symptomatic, VTE is associated with increased mortality [4]. Despite clear guidelines regarding prevention and treatment, the majority of VTE cases treated in French hospitals occur during the hospital stay [5].

Cancer is now an undoubted risk factor, with 15–20% of all VTE occurring in cancer patients [6]. There is a 7-fold increased risk of VTE in patients with cancer, and the risk is highest in the months following diagnosis [7]. The prevalence of VTE in cancer is estimated to be more than 2% in hospitalized patients [8]. Several risk factors have been described in cancer patients, including surgery, radiotherapy, chemotherapy and antiangiogenic treatments, metastatic stage, adenocarcinoma type, advanced stages of cancer, and hospitalization [6–12].

Lung cancer is increasingly frequent, and, in 2017, its estimated incidence in France was almost 50,000 new cases per year. It is the most common cause of death by cancer, with a 5-year survival rate of only 17% [13]. Lung cancer is one of the cancer types associated with the highest risk of developing VTE [7]. Hall et al. found an incidence of 6/100 person-years using the United States of America Medicare data [14], and Walker et al. found 39.2/1000 person-years using the United Kingdom health insurance database [15]. Though lung resection is an increasingly common treatment for lung cancer [16], this surgery increases the risk of VTE significantly. Platinum-based chemotherapies are another major treatment that appear to increase the risk of VTE [17].

VTE management in patients with cancer is further complicated by an increased risk of bleeding which is potentially exacerbated by anticoagulant therapies; about 10% of patients with cancer will present at least one bleeding event [18]. This can be explained by the tumour itself but can also be brought on by invasive surgery or chemo/radiotherapy-induced thrombocytopenia.

While the issues of VTE, major bleeding and survival in lung cancer patients have previously been studied in other countries, to the best of our knowledge, no study including both hospital and community treated VTE has been conducted in France.

Objective
The primary objective of this study was to evaluate the impact of VTE and major bleeding events on one-year survival after a primary lung cancer diagnosis in France. The secondary objective was to identify significant risk factors for VTE and major bleeding for this population.

Methods
Data source
Our study is based on the échantillon généraliste des bénéficiaires (EGB), a representative cross-sectional random sample (including hospital and out-of-hospital care) extracted from the total population database recorded by the French national insurance system (SNIIRAM - Système National d’Information Interrégime de l’Assurance Maladie) since 2004. The aim of the EGB database is to follow beneficiaries’ health care consumption over a period of 20 years. It was created using a systematic sampling method (1/97) based on the two-digit control key of beneficiaries’ national identification numbers, and it includes both current year reimbursement recipients and non-recipients. It is available to accredited researchers and contains the following individual, exhaustive and linkable but anonymous data [19]:

i) patients’ characteristics such as sex, age, date of death;
ii) the hospital discharge abstract database (Programme de Médicalisation des Systèmes d’Informations [PMSI]), which collects main and associated diagnoses encoded using the International Classification of Diseases 10th revision (ICD-10), and procedures performed during hospital stays (in all public and private hospitals), using the French common classification system for medical procedures (Classification Commune des Actes Médicaux [CCAM]);
iii) the reimbursement data for out-of-hospital care (consultations, procedures, drugs);
iv) the codes for long-term illnesses (Affection Longue Durée [ALD]), which provide patient coverage.

Various control procedures are regularly conducted to ensure the quality of these data. The reliability of the SNIIRAM, which initially included only the hospital database [16, 20–25] but more recently the whole database [26–28], has been established in recent studies.

Study population
We conducted a nationwide, population-based, retrospective study based on randomly sampled individuals older than 18 years old who were diagnosed with primary lung cancer in France from the 1st of January 2009 to the 31st December 2015. Inclusion criteria were a malignant tumour of the lungs or bronchus (ICD-10 code: C34) selected either in the ALD or PMSI hospital database.
Exclusion criteria were non-primary lung cancer defined as a diagnosis in the PMSI or an attachment to an ALD for an ongoing malignant tumour other than lung, bronchus and brain tumour within 5 years before lung cancer diagnosis.

To determine the date of lung cancer diagnosis, we retained the first date between the first ALD registration and the first hospital stay with a diagnosis of lung cancer.

Assessment of events
Follow-up started the day after the cancer diagnosis and was censored 1 year after. The availability of all data up to the 31st December 2016 made it possible to obtain a 1-year follow-up for all patients included. PE, DVT and bleeding events diagnosed during a hospital stay were identified from the associated ICD-10 codes in the PMSI database as a primary, related or associated diagnosis.

VTE diagnosed in ambulatory settings were identified in the EGB from the performance of investigations for VTE and by the delivery of a curative dose of anticoagulants within 8 days. The following investigations were identified: Doppler ultrasonography, pulmonary ventilation perfusion scintigraphy and CT pulmonary angiography. Data relative to the delivery of anticoagulants (heparin and oral anticoagulants) were collected. If an anticoagulant was delivered in the 72 h before the investigation exam, another delivery was required in the 2 following months. Therefore, patients for whom treatment was started before the investigation and then discontinued after a negative result were not misclassified as having VTE. We assumed that the events found only in an ambulatory setting were DVT seeing as a diagnosis of PE is more likely to be found in hospitalization data. We distinguished curative from preventive doses according to the quantities delivered, the time between two deliveries, duration of the treatment and national guidelines for VTE management. Major bleeding events were identified according to the ICD-10 codes selected in the NACORA-BR study [29], which also analysed major bleeding events in France using a similar database. All coded bleeding events were considered to be major because the presence of a code meant that patient management required hospitalization. Intracranial and digestive bleeding events were identified. We classified bleeding events as “other” if they were not digestive or intracranial (such as gynaecological or ocular), or if the ICD-10 code did not specify the bleeding area. The PMSI does not provide precise diagnosis dates, so the date of admission was considered to be the diagnosis date.

Events were analysed by an adjudication committee of three experts, an angiologist, a pneumologist and a pharmacist, who independently evaluated the plausibility of the occurrence of an event given the collected data.

Statistical analysis
Descriptive analyses were used to establish the population characteristics and to estimate the global frequency of VTE and major bleeding. Median survival with or without VTE or major bleeding were estimated using the Kaplan-Meier method.

A survival analysis was performed using Cox’s proportional hazard model to estimate the effect of VTE and major bleeding on one-year survival, adjusted for the other covariates. Treatment performance was introduced in the models as time-dependent covariates in order to take into account the time between the treatment and the event.

The Fine and Gray survival model was used to analyse VTE and major bleeding risk factors since death can be considered as a competitive risk with both of these events. Subdistribution hazard ratios (sHR) were estimated with this model.

Covariates included age, gender, Charlson’s comorbidity index (calculated with a previously validated algorithm [30] using information collected during the year preceding the inclusion), and concomitant diagnoses of VTE and cancer (defined as VTE occurring within 2 months before the date of cancer diagnosis or on the same date).

We also collected data concerning the presence of metastases, hospitalization and treatment (including chemotherapy, surgery (particularly for lung cancer), transfusion), bevacizumab, oral lung cancer targeted therapies and radiotherapy. Deliveries of anticoagulants, antiplatelet therapies and nonsteroidal anti-inflammatory drugs (NSAIDs) were also collected. All of the ICD-10, CCAM, CIP (Presentation Identification Code) and UCD (Common Dispensing Unit) codes used to collect the data are available online as supplementary material.

Similar analyses were performed specifically for PE occurrence and on the subgroup of patients presenting metastases.

For each survival analysis, all variables identified as significantly related to the occurrence of the event in a univariate analysis (using the Cox or Fine and Gray model) with a probability level of 0.20 were analysed in the multivariate regression model, except for age and gender which were systematically included. Proportional hazards and interactions were checked for each covariate. A backward selection of covariates was performed with a probability level of 0.05. Hazard ratios (HR) for Cox models or subdistribution hazard ratios (sHR) for Fine and Gray models are presented with 95% confidence intervals (CI). All analyses were performed with SAS software (SAS Institute Inc., Version 9.4, Cary, NC).

Ethical and regulatory aspects
Written consent was not needed for this non-interventional retrospective study. Access to the data
was granted on December 1st, 2016 (registration number 221) from the health data institute (Institut national des données de santé). The EGB database use was approved by the French national data protection agency (CNIL), and this study was conducted in accordance with the Declaration of Helsinki.

Results
A total of 2553 patients were included in the study. A VTE episode was identified in the year following the diagnosis of lung cancer for 208 (8.2%) patients and a major bleeding event was identified for 341 (13.4%) patients. Among the patients who presented with VTE, 93 presented with PE and 115 with DVT alone. A VTE event concomitant with cancer diagnosis was found for 64 patients (2.5%) and metastasis were identified in 1535 (60.1%) patients. Among the patients who presented with a major bleeding event, 55 had digestive bleeding, 22 intracranial bleeding and the others had other sites of bleeding. More than 45% of patients in this study (1175) died during follow-up.

Patients were aged 23 to 100 years old with a mean age of 67 years. Table 1 presents the patients’ demographic and clinical characteristics as well as the frequency of VTE and major bleeding according to these characteristics.

Primary objective: survival
Close to half of the patients who presented with VTE (104) died during follow-up. Among these patients, 56 presented with PE (accounting for 60.2% of the 93 patients with PE) and 48 presented with DVT alone (accounting for 41.7% of the 115 patients with DVT alone). The median survival time was 365.5 days for patients who presented with VTE and 439 days for those who did not. The mean time from PE to death was 105 ± 84 days, and 25% of these deaths occurred during the month following PE. The mean time from DVT alone to death was 124 ± 71, and 4% of these deaths occurred during the month following DVT. The median survival time was 326 days for patients who presented with major bleeding and 457 days for those who did not. Among the patients who presented with a major bleeding event, 186 died during follow-up (54.5%). The mean time from the major bleeding event to death was 89 ± 77 days, and 25% of these deaths occurred during the month following major bleeding. The median survival time was 355.5 days for patients who presented with VTE and major bleeding and 427 days for those who presented with neither VTE nor major bleeding. As shown in Table 2, VTE occurrence was associated with a significantly increased risk of death (HR = 1.53 [1.20–1.95] for PE and HR = 1.26 [1.01–1.57] for DVT), as was major bleeding occurrence (HR = 1.81 [1.54–2.12]).

Secondary objective: risk factors for VTE and major bleeding
VTE treatment was performed in an ambulatory setting for 49 patients (23.5%). More than 75% of VTE events occurred during the first 6 months following cancer diagnosis. A major bleeding event was found for 19 (9.1%) patients during the month following VTE. VTE occurred in 2 (0.6%) patients during the month following a major bleeding event.

Major treatments received during follow-up and before VTE, PE or major bleeding occurrence are described in Table 3.

VTE risk factors
Concomitant VTE and cancer diagnosis was associated with an increased risk of VTE recurrence beyond 6 months after the first VTE event (sHR = 4.07, 95% CI [1.57–10.52]). Although bevacizumab administration, radiotherapy, blood transfusion and non-surgical hospitalization were associated with VTE occurrence in the bivariate analysis, the only covariates remaining in the multivariable model were metastases (sHR = 1.83, 95% CI [1.30–2.58]), chemotherapy (sHR = 3.44, 95% CI [2.44–4.85]) and surgery other than lung cancer resection (sHR = 1.49, 95% CI [1.06–2.09]), as shown in Table 4. Lung cancer surgery and oral targeted therapies were not associated with an increased risk of VTE.

PE risk factors
Table 5 shows quite similar results for PE occurrence, but female gender was significantly associated with PE in the multivariable model (sHR = 1.68 [1.11–2.54]) whereas surgery and concomitant VTE and cancer diagnoses were no longer significant.

Major bleeding risk factors
The delivery of anticoagulants, antiplatelet therapies and NSAIDs before a major bleeding event are detailed in Table 6. Among patients presenting major bleeding, 78 (22.9%) had an anticoagulant treatment delivered during the 2 months preceding the event, 116 (34%) had an antiplatelet therapy delivered and 169 (49.6%) had either an anticoagulant or an antiplatelet therapy delivered. An NSAID treatment was delivered to 29 (8.5%) patients before a major bleeding event. The rate of major bleeding episodes in patients with VTE was 18.3% versus 12.9% in patients without VTE. Patients over 65 years old had an increased risk of bleeding (sHR = 1.40 [1.11–1.76]), as shown in Table 7, but women had a lower risk than men (sHR = 0.73 [0.57–0.94]). There were also highly significant increases in bleeding risk following a PE event (sHR = 2.90 [1.85–4.54]) and lung cancer surgery (sHR = 2.54 [1.88–3.45]). Chemotherapy, radiotherapy, surgery and metastasis were also found to be associated with the risk of major bleeding.
Subgroup analyses with patients presenting metastases provided similar results.

**Discussion**

**Survival**

In this study, the rate of death following VTE was high. This was especially true for patients who presented with PE since 60% of them died during follow-up. We also observed an elevated rate of death following major bleeding considering that 55% of these patients died within the follow-up period. This rate is consistent with the findings of Chouaid et al. in the TERRITOIRE study [31] in which the risk of death was significantly increased following PE and major bleeding events.

**VTE frequency and risk factors**

We report a high frequency (8%) of VTE after lung cancer diagnosis in France, with an increased risk of death

---

**Table 1** Patient demographics and clinical characteristics and probability of VTE and major bleeding

|                  | N (%) | VTE     | PE     | Bleeding |
|------------------|-------|---------|--------|----------|
| **Total**        | 2553  | 208 (8.21) | 93 (3.6) | 341 (13.4) |
| **Age**          |       |         |        |          |
| < 55             | 398 (15.6) | 45 (11.3) | 18 (4.5) | 42 (10.8) |
| 55–65            | 724 (28.4) | 73 (10.1) | 27 (3.7) | 83 (11.5) |
| 65–75            | 703 (27.5) | 54 (7.7)  | 24 (3.4) | 103 (14.7) |
| ≥ 75             | 728 (28.5) | 36 (5.0)  | 24 (3.3) | 112 (15.4) |
| **Gender**       |       |         |        |          |
| Male             | 1765 (69.1) | 141 (8.0) | 54 (3.1) | 260 (14.7) |
| Female           | 788 (30.9)  | 67 (8.5)  | 39 (4.9) | 81 (10.3)  |
| **Charlson’s comorbidity Index** |       |         |        |          |
| ≤ 5              | 1811 (70.9) | 159 (8.8) | 37 (2.7) | 239 (13.2) |
| > 5              | 742 (29.1)  | 49 (6.6)  | 56 (8.4) | 102 (13.8) |
| **Metastatic**   |       |         |        |          |
| No               | 1018 (39.9) | 41 (4.0)  | 16 (1.6) | 125 (12.3) |
| Yes              | 1535 (60.1) | 73 (4.7)  | 27 (1.8) | 216 (14.1) |
| **VTE concomitant with cancer diagnosis** |       |         |        |          |
| No               | 2489 (97.5) | 201 (8.1) | 90 (3.6) | 329 (13.2) |
| Yes              | 64 (2.5)    | 7 (10.9)  | 3 (4.7)  | 12 (18.8)  |
| **Anticoagulant or antiplatelet treatment** |       |         |        |          |
| No               | 1706 (66.8) | 158 (76.0) | 71 (76.3) | 199 (58.4) |
| Yes              | 847 (33.2)  | 50 (24.0) | 22 (23.7) | 142 (41.6) |
| **Anticoagulant therapy** |       |         |        |          |
| No               | 2338 (91.6) | 195 (8.3) | 86 (3.7) | 293 (12.5) |
| Yes              | 215 (8.4)   | 13 (6.1)  | 7 (3.3)  | 48 (22.3)  |
| **Antiplatelet therapy** |       |         |        |          |
| No               | 1851 (72.5) | 168 (9.1) | 78 (4.2) | 227 (12.3) |
| Yes              | 702 (27.5)  | 40 (5.7)  | 15 (2.1) | 114 (16.2) |
| **NSAID therapy** |       |         |        |          |
| No               | 2255 (88.3) | 175 (7.8) | 80 (3.6) | 311 (13.8) |
| Yes              | 298 (11.7)  | 33 (11.1) | 13 (4.4) | 30 (10.1)  |

|                | Univariate |       |       | Multivariate* |
|----------------|------------|-------|-------|---------------|
|                | HR (95% CI) | p-value | HR (95% CI) | p-value |
| **Age**        |            |        |        |               |
| < 55           | –          | –      | –      | –             |
| 55–65          | 0.91 (0.75–1.10) | 0.341 | 0.93 (0.77–1.26) | 0.450 |
| 65–75          | 1.00 (0.83–1.21) | 0.988 | 1.05 (0.87–1.27) | 0.609 |
| ≥ 75           | 1.75 (1.46–2.09) | < 0.0001 | 2.02 (1.69–2.42) | < 0.0001 |
| **Gender**     |            |        |        |               |
| Male           | –          | –      | –      | –             |
| Female         | 0.89 (0.78–1.01) | 0.061 | 0.85 (0.75–0.97) | 0.013 |
| **Metastasis** |            |        |        |               |
| No             | 3.46 (2.77–4.32) | < 0.0001 | 4.39 (3.83–5.03) | < 0.0001 |
| Yes            | 2.43 (1.94–3.06) | < 0.0001 | 1.53 (1.20–1.95) | 0.0006 |
| **PE after cancer diagnosis** |            |        |        |               |
| No             | 1.60 (1.29–1.97) | < 0.0001 | 1.26 (1.01–1.57) | 0.043 |
| Yes            | 2.17 (1.86–2.54) | < 0.0001 | 1.81 (1.54–2.12) | < 0.0001 |

*Multivariate analysis adjusted for age and gender
after VTE occurrence. This result is consistent with other studies such as the FRAGMATIC trial, where 9.7% of newly diagnosed patients with no low-molecular-weight heparin prophylaxis presented with VTE [32]. While VTE is a well-established prognosis factor in cancer patients [33], we demonstrate that clinical and therapeutic factors such as chemotherapy, surgery and the presence of metastases are related to VTE occurrence. Concomitant VTE and cancer diagnoses are associated with an increased risk of VTE after cancer diagnosis, with a sHR of 4.07 [1.57–10.52]. This result calls into question the effectiveness of VTE management.

Table 3  Treatments and hospitalizations for patients within 1 year after lung cancer diagnosis

|                          | Total (N = 2553) | Before VTE (N = 208) | Before PE (N = 93) | Before bleeding (N = 341) |
|--------------------------|------------------|----------------------|--------------------|--------------------------|
| Lung cancer surgery      |                  |                      |                    |                          |
| No                       | 2052 (80.4)      | 181 (87.0)           | 83 (89.3)          | 280 (82.1)               |
| Yes                      | 501 (19.6)       | 27 (13.0*)           | 10 (10.8)          | 61 (17.9)                |
| Other surgery            |                  |                      |                    |                          |
| No                       | 1970 (77.2)      | 156 (75.0)           | 73 (78.5)          | 279 (81.8)               |
| Yes                      | 583 (22.8)       | 52 (25.0)            | 20 (21.5)          | 62 (18.2)                |
| Chemotherapy             |                  |                      |                    |                          |
| No                       | 1201 (47.0)      | 72 (34.6)            | 35 (37.6)          | 217 (63.6)               |
| Yes                      | 1352 (53.0)      | 136 (65.4)           | 58 (62.4)          | 124 (36.4)               |
| + Bevacizumab            |                  |                      |                    |                          |
| No                       | 1244 (92.0)      | 125 (91.9)           | 55 (91.4)          | 117 (94.4)               |
| Yes                      | 108 (8.0)        | 11 (8.1)             | 3 (8.6)            | 7 (5.7)                  |
| Oral lung cancer targeted therapy |          |                      |                    |                          |
| No                       | 2340 (91.7)      | 201 (96.6)           | 87 (93.6)          | 333 (97.7)               |
| Yes                      | 213 (8.3)        | 7 (3.4)              | 6 (6.5)            | 8 (2.4)                  |
| Radiotherapy             |                  |                      |                    |                          |
| No                       | 1711 (67.0)      | 155 (74.5)           | 68 (73.1)          | 274 (80.4)               |
| Yes                      | 842 (33.0)       | 53 (25.5)            | 25 (26.9)          | 67 (19.7)                |
| Blood transfusion        |                  |                      |                    |                          |
| No                       | 2253 (88.3)      | 190 (91.4)           | 86 (92.5)          | 290 (85.0)               |
| Yes                      | 300 (11.8)       | 18 (8.7)             | 7 (7.5)            | 51 (15.0)                |
| Non-surgical hospitalisation |            |                      |                    |                          |
| No                       | 1065 (41.7)      | 122 (58.7)           | 52 (55.9)          |                          |
| Yes                      | 1488 (58.3)      | 86 (41.4)            | 41 (44.1)          |                          |

*Among patients with VTE, 13.0% underwent lung cancer surgery after the diagnosis of cancer and before the diagnosis of VTE
†Non-surgical stay of more than 2 nights

Table 4  Risk factor analysis for venous thromboembolism (VTE) occurrence within 1 year after lung cancer diagnosis

|                          | Univariate          | Multivariate**       |
|--------------------------|---------------------|----------------------|
|                          | sHR (95% CI)        | p-value              |
| Age                      |                     |                      |
| < 55                     | –                   | –                    |
| 55–65                    | 0.89 (0.61–1.28)    | 0.519                |
| 65–75                    | 0.66 (0.45–0.99)    | 0.042                |
| ≥ 75                     | 0.42 (0.27–0.65)    | 0.0001               |
| Gender                   |                     |                      |
| Male                     | –                   | –                    |
| Female                   | 1.07 (0.80–1.43)    | 0.650                |
| Metastasis               | 2.86 (2.12–3.86)    | < 0.0001             |
| VTE concomitant with cancer diagnosis | 4.26 (1.67–10.88) | 0.003                |
| Lung cancer surgery      | 0.96 (0.64–1.44)    | 0.955                |
| Other surgery            | 2.05 (1.48–2.82)    | < 0.0001             |
| Chemotherapy             | 4.63 (3.45–6.23)    | < 0.0001             |
| Bevacizumab              | 2.39 (1.29–4.42)    | 0.006                |
| Oral targeted therapy    | 1.19 (0.56–2.54)    | 0.655                |
| Radiotherapy             | 1.95 (1.41–2.71)    | < 0.0001             |
| Blood transfusion        | 1.91 (1.16–3.15)    | 0.012                |
| Non-surgical hospitalization | 1.53 (1.16–2.03)  | 0.003                |

*Risk of recurrent VTE beyond 6 months after the first VTE
**Multivariate analysis adjusted for age and gender
for these patients. As suggested by Piran et al. [34], treatment and surveillance protocols may not be effective enough to prevent VTE recurrence. Patient adherence to treatment is another potential issue. In future studies, it would be interesting to analyse the use of anticoagulation therapies (type, duration) when prophylaxis is recommended for these patients.

Chemotherapy was found to be majorly associated with the risk of VTE (3.44 sHR), which is consistent with previously published studies [35]. According to the literature, this risk is increased particularly during chemotherapy and for a month after discontinuation [36, 37]. The BIOTEL study showed that 15% of lung cancer patients presented with VTE within 6 months after initiating chemotherapy [38], Connolly et al. found 13.9% [37], and Khorana et al. found 12.6% [17]. More recently, Rupa-Matysek et al. reported that 16.9% of patients undergoing chemotherapy developed VTE [39]. Currently, some international guidelines suggest the use of primary thromboprophylaxis for metastatic lung cancer patients with low bleeding risk receiving chemotherapy [40].

Lung cancer surgery had a protective effect in the bivariate analysis, which is likely explained by the fact that this surgery is reserved for patients with a better prognosis. Only non-lung-cancer surgeries had a significant effect on VTE occurrence in the multivariable model (1.49

**Table 5** Risk factor analysis for PE occurrence within 1 year after lung cancer diagnosis

| Risk factor | Univariate | Multivariate** |
|-------------|------------|----------------|
|             | sHR (95% CI) | p-value | sHR (95% CI) | p-value |
| Age         |            |         |              |         |
| < 55        | –          | –       | –            | –       |
| 55–65       | 0.82 (0.45–1.48) | 0.503 | 0.88 (0.48–1.60) | 0.665 |
| 65–75       | 0.75 (0.40–1.37) | 0.346 | 0.91 (0.49–1.70) | 0.774 |
| ≥ 75        | 0.72 (0.39–1.33) | 0.294 | 1.08 (0.56–2.08) | 0.828 |
| Gender      |            |         |              |         |
| Male        | –          | –       | –            | –       |
| Female      | 1.63 (1.08–2.47) | 0.020 | 1.68 (1.11–2.54) | 0.014 |
| Metastasis  | 3.46 (2.18–5.50) | < 0.0001 | 2.51 (1.48–4.26) | 0.0006 |
| VTE concomitant with cancer diagnosis* | 3.33 (0.80–13.97) | 0.100 |
| Lung cancer surgery | 0.78 (0.41–1.50) | 0.456 |
| Other surgery | 1.64 (0.98–2.75) | 0.061 |
| Chemotherapy | 3.97 (2.58–6.09) | < 0.0001 | 3.13 (1.88–5.20) | < 0.0001 |
| Bevacizumab | 1.39 (0.44–4.42) | 0.577 |
| Oral targeted therapy | 2.38 (1.02–5.53) | 0.045 |
| Radiotherapy | 2.10 (1.29–3.43) | 0.003 |
| Blood transfusion | 1.53 (0.70–3.34) | 0.286 |
| Non-surgical hospitalization | 1.74 (1.14–2.65) | 0.011 |

*Risk of recurrent VTE beyond 6 months after the first VTE
**Multivariate analysis adjusted for age and gender

**Table 6** Treatments delivered during the 2 months preceding a major bleeding event after lung cancer diagnosis

| Treatment                        | Total (n = 341) | Digestive (n = 267) | Intracranial (n = 28) | Other (n = 248) |
|----------------------------------|-----------------|---------------------|-----------------------|-----------------|
| N (%)                            | (n = 341)       | Digestive           | Intracranial          | Other           |
| Total                            | 55 (16.1)       | 22 (6.5)            | 264 (77.4)            |                 |
| Anticoagulant or antiplatelet treatment |                  |                     |                       |                 |
| No                               | 172 (50.4)      | 26 (47.3)           | 8 (36.4)              | 138 (52.3)      |
| Yes                              | 169 (49.6)      | 29 (52.7)           | 14 (63.6)             | 126 (47.7)      |
| Anticoagulant therapy            |                  |                     |                       |                 |
| No                               | 263 (77.1)      | 40 (72.7)           | 16 (72.7)             | 207 (78.4)      |
| Yes                              | 78 (22.9)       | 15 (27.3)           | 6 (27.3)              | 57 (21.6)       |
| Antiplatelet therapy             |                  |                     |                       |                 |
| No                               | 225 (66.0)      | 37 (67.3)           | 11 (50.0)             | 177 (67.1)      |
| Yes                              | 116 (34.0)      | 18 (32.7)           | 11 (50.0)             | 87 (32.9)       |
| NSAID treatment                  |                  |                     |                       |                 |
| No                               | 312 (91.5)      | 50 (90.9)           | 19 (86.4)             | 243 (92.1)      |
| Yes                              | 29 (8.5)        | 5 (9.1)             | 3 (13.6)              | 21 (7.9)        |
Surgery is a well-known risk factor for VTE, and its association with the thrombogenic state induced by cancer can explain part of this risk. However, it is not clear whether prophylaxis guidelines were properly followed for these patients.

Surprisingly, female gender seemed to be associated with a higher risk of PE. Women of childbearing age have been found to present a higher risk of VTE than men [5], which was explained by hormonal factors, but most of the women included in our study were no longer of childbearing age.

Bevacizumab was not significantly associated with events in the multivariable model. As all patients receiving bevacizumab were also undergoing chemotherapy, the effect of the two treatment regimens cannot be distinguished. However, when chemotherapy was not integrated in the multivariable models, bevacizumab was not significantly associated with VTE occurrence.

Non-surgical hospitalization is a major risk factor for VTE in the general population as it induces immobilization, but it does not appear to increase significantly the risk of VTE in lung cancer patients. These patients are more likely to be hospitalized and are exposed to other more significant risk factors which probably lessen the overall effect of hospitalization.

Major bleeding frequency and risk factors
We also report frequent major bleeding events (13%) after a lung cancer diagnosis. In patients presenting with major bleeding, in the two previous month more than 22% had taken anticoagulant therapy and more than 30% antiplatelet therapy. It is interesting to note that half of bleeding events were seemingly not related to a pharmacological factor. NSAIDs were delivered to 8% of our patient population before the event, but no information on self-medication is available in the database. The rate of major bleeding episodes is higher for patients with VTE (18.3%) than for those without (12.9%). However, these rates are to interpret cautiously since follow-up started on the date of the cancer diagnosis (the primary objective being survival) and we only had information on the first bleeding event during follow-up. Major bleeding events may have occurred before the episode of VTE.

The risk of major bleeding was higher for patients over 65 years old and for men, even though gynaecologic bleeding was included. PE was identified as a significant risk factor for major bleeding, which can be explained by the addition of an anticoagulant therapy. An increased risk of major bleeding was found for patients taking anticoagulant or antiplatelet therapy, but not NSAIDs. The risk was also significantly increased after surgery, especially after lung cancer resection, which probably reflects the invasiveness of the procedure. Chemotherapy also seems to be associated with an increased risk of major bleeding, which could be explained by the haematological damage induced. Bevacizumab did not increase the risk of major bleeding.

Study strengths and limitations
This is the first French study on VTE following cancer diagnosis which assesses the risk of various cancer risk factors and major bleeding. The strengths of our study include the large sample size, the prospective design, and the comprehensive collection of data on all patients. However, the limitations of our study include the potential for selection bias, as the study was conducted in a single institution, and the potential for recall bias.

Table 7 Risk factor analysis for major bleeding occurrence within 1 year after lung cancer diagnosis

| Risk Factor                        | Univariate | Multivariate* |
|------------------------------------|------------|---------------|
|                                    | sHR (95% CI) | p-value | sHR (95% CI) | p-value |
| Age                                |            |          |            |          |
| < 65                               | –          | –        | –          | –        |
| ≥ 65                               | 1.38 (1.11–1.71) | 0.004       | 1.40 (1.11–1.76) | 0.005       |
| Gender                             |            |          |            |          |
| Male                               | –          | –        | –          | –        |
| Female                             | 0.68 (0.53–0.87) | 0.002       | 0.73 (0.57–0.94) | 0.016       |
| Metastasis                         | 1.58 (1.26–1.98) | < 0.0001 | 1.38 (1.08–1.78) | 0.011       |
| PE                                 | 2.88 (1.83–4.52) | < 0.0001 | 2.90 (1.85–4.54) | < 0.0001     |
| DVT                                | 1.53 (0.96–2.43) | 0.074       |             |          |
| Anticoagulant therapy              | 1.91 (1.41–2.59) | < 0.0001 | 1.77 (1.30–2.43) | 0.0003       |
| Antiplatelet therapy               | 1.36 (1.09–1.71) | 0.007       | 1.27 (1.01–1.60) | 0.044       |
| NSAID therapy                      | 0.71 (0.49–1.03) | 0.075       |             |          |
| Lung cancer surgery                | 1.79 (1.33–2.42) | 0.0001      | 2.54 (1.88–3.45) | < 0.0001     |
| Other surgery                      | 1.68 (1.26–2.23) | 0.0004      | 1.50 (1.11–2.02) | 0.009       |
| Chemotherapy                       | 1.66 (1.30–2.13) | < 0.0001 | 1.54 (1.19–2.00) | 0.001       |
| Bevacizumab                        | 1.04 (0.49–2.21) | 0.919       |             |          |
| Oral targeted therapy              | 0.97 (0.47–1.97) | 0.925       |             |          |
| Radiotherapy                       | 1.80 (1.34–2.41) | 0.0001      | 1.71 (1.25–2.34) | 0.001       |

*Multivariate analysis adjusted for age and gender
treatments. One of its great strengths resides in the large number of patients included in a real-life setting. According to the National Institute of Cancer, 37,000 cases-year of lung cancer were diagnosed in France (2012 data) [41]. Therefore, about 259,000 cases of lung cancer should have been diagnosed in the whole population during the 7-year study period. Since we would expect to see about 2670 cases of lung cancer in a random sample like ours (1/97th of the whole population), our population of 2553 cases is consistent, which means that the present study can draw relevant conclusions on a national level. Another strength of this study is that we included VTE treated in an ambulatory setting even though cases were deduced indirectly. This is unlike most studies which only include patients treated in hospital, thus minimizing the extent of this issue. VTE treated in ambulatory care accounts for more than 20% of all VTE events in our study. Moreover, we introduced time-dependent covariates in the models. This allowed us to take into account the time between the treatment and the event and to estimate their effect more precisely by giving the appropriate weight to events occurring shortly after the treatment of interest.

The main limitation of this study is that the cause of death is not reported in the EGB, so we were only able to analyse overall survival. Some patients may have died from VTE, but this information was not assessable. However, real-life overall survival is still a clinically relevant indicator. We used a Fine and Gray model to analyse this competing risk setup (VTE and death). Further studies with access to the cause of death are needed to estimate the frequency of deaths that are a direct result of VTE events.

There is also an issue regarding the diagnosis dates provided by this database. However, the diagnosis date for cancer rarely marks the actual beginning of the disease, so the slight inaccuracy of these dates may not be clinically relevant. We cannot exclude that some of the dates were reported later than the actual diagnosis date, but the effect should be negligible considering the large size of the cohort. Moreover, we were able to study the chronology between events by introducing time-dependent variables in the model. Even though dates are imprecise, this allowed us to correctly qualify the exposure to each risk before the event for every patient, and this should not bias the results.

Another limitation is that some known risk factors for VTE such as cancer type, stage and mutational status were not available in this database. Other prognosis factors that are used to calculate a prognostic score validated in lung cancer patients were not available either, including smoking status, respiratory comorbidities and weight loss [42]. However, we did adjust for the presence of metastases in our model, which appears to be a major risk factor according to the literature.

It is interesting to notice the consistency of the results when we analysed the subgroup of patients with metastases. Even though the information concerning the presence of metastases may not be complete in the database, we can consider it reliable when available. An indication bias can be questioned seeing as bevacizumab, which is known to increase VTE and bleeding risk, was not found to be a risk factor in our study. This could be due to a selection of lower-risk patients for bevacizumab treatment. Furthermore, biological data such as platelet, hemoglobin and leukocyte levels were not available.

The chemotherapy agents used were not available in the database either, which is unfortunate because they appear to be predictive factors for VTE and major bleeding events. Lastly, we were only able to include patients up to 2015 to ensure a one-year follow-up with the data available. Given the rapid changes in lung cancer management over the last few years, analyses on more recent data could make a difference in these results.

Conclusion
This is the first study to explore both VTE and major bleeding in patients diagnosed with lung cancer in France. We found a high frequency of VTE and an even higher frequency of major bleeding following a lung cancer diagnosis. As both VTE and major bleeding were shown to be significantly associated with decreased survival, and most major bleeding events were seemingly not related to a pharmacological factor, we may hypothesize that VTE and major bleeding could be considered independently as indicators of the worsening of lung cancer.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-06930-1.

Additional file 1.

Abbreviations
VTE: Venous thromboembolism; DVT: deep vein thrombosis; PE: pulmonary embolism; EGB: échantillon généraliste des bénéficiaires; SNIIRAM: Système National d’Information Interrégime de l’Assurance Maladie; PMSI: Programme de Médicalisation des Systèmes d’Informations; ICD-10: International Classification of Diseases 10th revision; CCAM: Classification Commune des Actes Médicaux; ALD: Affection Longue Durée; CT: computed tomography; sHR: Subdistribution hazard ratios; NSAIDs: nonsteroidal anti-inflammatory drugs; LCD: Common Dispensing Unit; HR: hazard ratios; CI: confidence intervals; INDS: Health data institute (Institut national des données de santé); CNIL: French national data protection agency

Acknowledgements
The authors thank Suzanne Rankin for reviewing the English.

Authors’ contributions
JH and CQ conceptualized and designed the study, interpreted the data. JH wrote the paper. CQ oversaw the data analysis and interpretation, and contributed to writing the manuscript. PFa, PFO participated in the adjudication committee. EB and JC performed data analysis and contributed
to writing the manuscript. FPa, PFro participated in the interpretation of the results reviewed and revised the manuscript drafts. All authors accept responsibility for the paper as published. All authors have read and approved the manuscript.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

Our study is based on the EGB random sample (including hospital and out-of-hospital care) extracted from the total population database recorded by the National Insurance system and made available (1/97th of the whole population) to accredited researchers that contains individual, exhaustive and linkable but anonymous data. We are not allowed to transmit these data.

**Ethics approval and consent to participate**

Written consent was not necessary for this non-interventional retrospective observational study. Consent for publication was not needed for this non-interventional retrospective observational study.

**Competing interests**

The authors have no conflicts of interest relevant to this article to disclose.

**Author details**

1. CHRU Dijon, Pharmacy, F-21000 Dijon, France. 2. Biostatistics and Bioinformatics (DMI), University Hospital, Bourgogne Franche-Comté University, Dijon, France. 3. INSERM, CIC 1432, Clinical Investigation Center, Bioinformatics (DIM), University Hospital, Bourgogne Franche-Comté 4. Department of Thoracic Oncology CHU, Dijon, France. 5. Unité INSERM U866, Dijon University Hospital, Dijon, France. 6. Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), INSERM, UVSQ, Institut Pasteur, Université Paris-Saclay, Paris, France.

**Received:** 29 January 2020 Accepted: 5 May 2020

**Published online:** 24 May 2020

**References**

1. Allaint F-A, Benzenine E, Quantin C. Hospital incidence and annual rates of hospitalization for venous thromboembolic disease in France and the USA. Phlebology. 2017;32(7):443–7.

2. Boule S, Ereny C, Samson A, Gourmelen J, Baillly C, Cotté F. Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J. 2016;14:4.

3. Arshad N, Bjørn E, Hindberg K, Isaksen T, Hansen J-B, Braekkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost JTH. 2017;15(2):295–303.

4. Vaitkus P, Leitnorovac A, Cohen A, Turpie A, Olsson C-G, Goldhaber S. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005;93(1):76–9.

5. Allaint F, Benzenine E, Quantin C. More than one in two venous thromboembolism treated in French hospitals occurs during the hospital stays. Phlebology. 2016;31(6):390–6.

6. Heit J, Silverstein M, Mohr D, Petterson T, O’Fallon W, Melton L. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–15.

7. Blom J, Doggen C, Osanto S, Rosendaal F. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.

8. Stein P, Beemath A, Meyers F, Skaf E, Sanchez J, Olson R. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60–8.

9. Walker A, Card T, West J, Crooks C, Grainge M. Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13.

10. Guy J-B, Bertoletti L, Magnin N, Rancoule C, Mahé I, Font C, et al. Venous thromboembolism in radiation therapy cancer patients: findings from the RITE registry. Crit Rev Oncol Hematol. 2017;113:83–9.

11. Kadlec B, Skrickova J, Merta Z, Dusek L, Jarkovsky J. The incidence and predictors of thromboremoembolic events in patients with lung cancer. ScientificWorldJournal. 2014;2014:125706.

12. Chew H, Davies A, Wun T, Harvey D, Zhou H, White R. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6(6):501–8.

13. Institut National du Cancer (INCa). Cancer du poumon: quelques chiffres [Internet]. [cited 2018 May 10]; Available from: http://www.eve-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-du-poumon.

14. Hall IE, Andersen MS, Krumholz HM, Gross CP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol. 2009;2009:1–9.

15. Walker A, Baldwin D, Card T, Powell H, Hubbard R, Grainge M. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. Br J Cancer. 2016;115(1):115–21.

16. Pages P, Cottenet J, Mariet A, Bernard A, Quantin C. In-hospital mortality following lung cancer resection: nationwide administrative database. Eur Respir J. 2016;47(6):1809–17.

17. Khorana A, Dalal M, Lin J, Connolly G. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–55.

18. Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review: Annals of Palliative Medicine apr. 2018;7(2):265–73.

19. Goldberg M, Jougla E, Fassa M, Padieu R, Quantin C. The French health information system. Journal of the International Association for Official Statistics. 2012;28:31–41.

20. Guimano M, Rodvin W, Weisz D, Cottenet J, Quantin C. Comparison of rehospitalization rates in France and the United States and the French States. J Health Serv Res Policy. 2015;20(1):18–25.

21. Lorigs L, Cottenet J, Molins G, Benzenine E, Zeller M, Aube H, et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation. 2013;127(17):1767–74.

22. Lainay C, Benzenine E, Durier J, Daubal B, Groud M, Quantin C, et al. Hospitalization within the first year after stroke: the Dijon stroke registry. Stroke. 2015;46(1):190–6.

23. Creuzot-Garcher C, Benzenine E, Mariet A-S, de Lazzer A, Chiquet C, Bron AM, et al. Incidence of acute postoperative Endophthalmitis after cataract surgery: a Nationwide study in France from 2005 to 2014. Ophthalmology. 2016;123(7):1414–20.

24. Goueslard K, Cottenet J, Mariet A-S, Groud M, Cotton Y, Pettit J-M, et al. Early cardiovascular events in women with a history of gestational diabetes mellitus. Cardiovasc Diabetol. 2016;15:15.

25. Vergès B, Patois-Vergès B, Goueslard K, Cottenet J, Nguyen A, Tatulashvili S, et al. High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS): The REHABDIAB study. Diabetes Metab. 2017.

26. Quantin C, Benzenine E, Velten M, Huert F, Farrington CP, Tubert-Bitter P. Self-controlled case series and misclassification bias induced by case selection from administrative hospital databases: application to febrile convulsions in pediatric vaccine pharmacoepidemiology. Am J Epidemiol. 2013;178(12):1751–9.

27. Harf M, Quantin C, Farrington P, Benzenine E, Hocine NM, Velten M, et al. Validation of the French national health insurance information system as a tool in vaccine safety assessment: application to febrile convulsions after pediatric measles/mumps/rubella immunization. Vaccine. 2013;31(49):5856–62.

28. Goueslard K, Cottenet J, Mariet A-S, Sagot P, Petit J-M, Quantin C. Early screening for type 2 diabetes following gestational diabetes mellitus in France: hardly any impact of the 2010 guidelines. Acta Diabetol. 2015;52(7):645–51.

29. Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS). Étude ‘En vie réelle’ du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des antivitamines K. Étude NACORA-BR du projet NACORA (nouveaux anticoagulants oraux et risques
30. Bannay A, Chaignot C, Blotère P-O, Basson M, Weill A, Ricordeau P, et al. The best use of the Charlson comorbidity index with electronic health care database to predict mortality. Med Care. 2016;54(2):188–94.

31. Chouaïd C, Debieuvre D, I. Durand-Zaleski I, Fernandes J., Scherpereel A, Westeel V, Blein C, Gaudin A, Otsan N, Leblanc S, Vainchtock A, Cotté F, Souquet P. Disparités régionales et socio-économiques dans le cancer du poumon (étude TERRITOIRE). Rev. Mal. Resp. 2016;33(S):A21.

32. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Pajon P, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. J Clin Oncol. 2016;34(5):488–94.

33. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.

34. Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb Res. 2018;164(Suppl 1):S172–7.

35. Huang H, Korn J, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis. 2012;34(4):446–56.

36. Kuderer NM, Poniewierski MS, Cukajova E, Lyman GH, Khorana AA, Pabinger I, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist. 2018;23(2):247–55.

37. Connolly G, Dalai M, Lin J, Khorana A. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253–8.

38. Alexander M, Ball D, Solomon B, MacManus M, Manser R, Riedel B, Westerman D, Evans S, Wolfe R, Burbury K. Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. Cancers (Basel). 2019;11(1):50.

39. Rupa-Matysek J, Lembicz M, Rogowska E, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35(5):63.

40. Farge D, Bounnameaux H, Brenner B, Caflinger F, Deboudreaux P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–66.

41. UNICANCER - Figures for cancer in France [Internet]. [cited 2018 Aug 13]. Available from: http://www.unicancer.fr/en/unicancer-group/key-figures/figures-cancer-france42. Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. Thromb Res. 2018;164:570–8.

42. Alexander M, Wolfe R, Ball D, Conron M, Stirling RG, Solomon B, MacManus M, Officer A, –Karnam S, Burbury K, Evans SM. Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer. 2017;117(5):744–751.